Study of Nesvacumab (REGN910/ SAR307746)

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) administered IV every 2 weeks.

Key facts

Study ID

NCT01271972

Run by

Regeneron Pharmaceuticals

People needed

53

Starts

2011-01-01

Expected to finish

2015-05-01

Last updated by the study team

2015-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of advanced solid malignancy.
• ECOG performance status 0 - 1
• Adequate hepatic, renal and bone marrow function
• At least 3 weeks since last dose of chemotherapy, hormonal therapy or radiotherapy
• At least 6 weeks since last dose of bevacizumab
• At least 4 weeks since last surgery
• At least 4 weeks since last dose of investigational treatment

You may not qualify if…

• Patients with brain metastases, spinal cord compression, carcinomatous meningitis, or other evidence of central nervous system involvement
• Patients with serious non healing wound or acute ulcer
• Either systolic blood pressure >150 mm Hg or diastolic blood pressure >95 mm Hg
• Patients with medical history of myocardial infarction, unstable angina pectoris, coronary/ peripheral artery bypass graft, congestive heart failure or ventricular arrhythmia
• Patients with deep vein thrombosis or pulmonary embolism within last 6 months

Where it is running

• Study site — San Francisco, California, United States
• Study site — San Antonio, Texas, United States
• Study site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.